When will the FINASTERIDE AND TADALAFIL patents expire, and when will FINASTERIDE AND TADALAFIL go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	FINASTERIDE AND TADALAFIL	finasteride; tadalafil	CAPSULE;ORAL	218499-001	Mar 19, 2025		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Lifesciences	FINASTERIDE AND TADALAFIL	finasteride; tadalafil	CAPSULE;ORAL	218232-001	Mar 15, 2024		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 8, 2026

Finasteride and tadalafil are mature, high-volume products with established FDA presence and global manufacturing footprints. Investment upside is primarily tied to (1) branded re-positioning, (2) combination-product strategy, (3) competitive erosion timing across geographies, and (4) whether patents still meaningfully restrict formulation, delivery, or new indications. Patent control typically concentrates in method-of-use and specific formulations rather than the core APIs, so near-term returns depend on launch timing versus generic and on any remaining secondary exclusivities.

Do finasteride and tadalafil have an investable patent estate, or is it already generic-exposed?

Bottom line: Both actives have strong historical patent footprints but currently trade in a market characterized by extensive generic penetration. A new investment case hinges on whether a specific commercial product includes still-protected secondary IP (new salt, polymorph, dosage form, controlled release, fixed-dose combinations, or new dosing regimens) and whether exclusivity blocks generic entry in key jurisdictions.

How many “active” patents typically remain relevant for finasteride and tadalafil in 2024–2027?

Finasteride

Core API patent protection largely cleared in major markets long ago.
Residual value often resides in:
- formulation patents (dose form, release profile)
- combination and fixed-dose products
- method-of-use expansions and specific patient subgroups
- manufacturing-process improvements (less commonly investment-dominant)

Tadalafil

Core API patents also largely cleared in the major markets.
Residual value often resides in:
- new formulations (eg, alternative release or dose forms)
- new medical use and dosing regimens
- combination products

What does this mean for investors?

If the target investment is a generic-equivalent dossier or manufacturing capacity, the case compresses to gross margin and scale.
If the target is a branded or specialty formulation with fixed-dose or delivery differentiation, the case depends on still-enforceable secondary claims and any regulatory exclusivities.

What patents protect finasteride and tadalafil products in the US and Europe?

Featured snippet answer: Patents protecting current commercial products are typically secondary: formulations, dosing regimens, fixed-dose combinations, and certain method-of-use claims. Core composition-of-matter is usually expired in major markets for these APIs.

H1 cluster: US patent coverage patterns

Finasteride

Typical remaining IP categories:
- method-of-use claims for specific BPH or prostate-volume cohorts
- formulation patents for tablets and dose strengths
- combination claims where finasteride is paired with other urology agents

Tadalafil

Typical remaining IP categories:
- method-of-use claims for erectile dysfunction (ED) and/or other approved indications (as available)
- formulation and dosing regimen patents (where they exist for specific products)
- combination product claims

H1 cluster: Europe and UK

Europe often sees similar secondary-IP concentration.
Enforcement value depends on:
- claim scope clarity in each country
- whether any granted patents remain in force
- whether litigation history or consent judgments narrowed enforceability

When does finasteride and tadalafil lose exclusivity in key markets?

Bottom line: For both APIs, primary exclusivity is typically long expired in the US and EU. Investors should model exclusivity at the product level, not the API level, and treat remaining patent life as mostly secondary.

US regulatory exclusivity vs patents

Orange Book listings drive formulary and generic entry timing for listed patents.
For mature small molecules, generic entry usually occurs when listed patents expire or are found not infringed or invalid in a Paragraph IV pathway.

How to model “loss of exclusivity” in practice

Use a two-layer model:

Regulatory barrier layer: any listed FDA Orange Book patents tied to the marketed strength/dosage form.
Litigation barrier layer: any active disputes and whether injunctions or settlement agreements delay entry.

What is the Orange Book status of finasteride and tadalafil products?

Featured snippet answer: Orange Book status determines whether generics can enter without risking infringement. For widely available APIs like these, many products show expired patent barriers for the majority of strengths/dosage forms, with remaining listings concentrated in specific branded formulations.

Investment implication

If an investment target relies on Orange Book-listed patents, the revenue risk is the probability of generic launch at the earliest non-blocked date.
If the target is a new fixed-dose combination or delivery system, Orange Book coverage may be narrower but more protective, depending on patent listings and strength-specific claims.

What generic entry risks exist for finasteride and tadalafil combination products?

Bottom line: The combination concept introduces a narrower but potentially higher-value IP field: fixed-dose claims and specific dosing regimens. That said, if the combination is not protected by valid, enforceable claims, generics can enter using either:

a combination approval strategy, or
separate authorization strategies that still compete at the patient level.

Paragraph IV vs “non-Paragraph IV” generic entry

Paragraph IV is relevant where Orange Book patents are listed and challenged.
If products are fully unblocked, generics can file and launch without needing a Paragraph IV dispute.

Key risk drivers

Strength/dosage form specificity: even if one strength is protected, others may not be.
Bioequivalence and approval pathway: if the generic can meet BE without infringing formulation claims.
Narrow claim scope: some secondary patents are easy to design around (different excipients, dissolution profile, or manufacturing method).

How strong is the patent estate for finasteride and tadalafil in fixed-dose combinations?

Featured snippet answer: Fixed-dose combination IP strength typically concentrates in:

claims specifying the ratio of actives,
claims specifying a dosing schedule,
and claims specifying the formulation attributes enabling therapeutic performance.

What “strong” looks like for investment

Multiple independent claims across:
- composition/formulation
- method-of-use/dosing
- manufacturing process (if hard to design around)
Track record of survived litigation for similar claims in the portfolio
No widespread “easy design-around” history for the same concept

What “weak” looks like

Single-claim dependence on specific excipients or a narrow particle-size range
Litigation history showing claim narrowing at the PTAB or in court
Settlement terms that permit early generic entry for major players

What patent litigation affects finasteride and tadalafil commercialization?

Bottom line: Litigation history for mature APIs is often extensive historically, but current investment impact is driven by any active disputes around a specific branded product, strength, or new combination. For these APIs as stand-alone actives, most large litigation risk is resolved. For combination products and newer formulations, litigation can still be active.

How litigation outcomes typically map to investment

Court wins that preserve an injunction risk delay and can support premium pricing.
Settlement agreements often translate into “carve-out” dates for specific entrants and strengths.
PTAB invalidations can remove Orange Book blocking patents and accelerate generic schedules.

Do settlement agreements delay generic launches of finasteride and tadalafil?

Featured snippet answer: For mature small molecules, settlements are common when Orange Book-listed patents are asserted. The investment question is whether the target product is in the “still-settled” window for major strengths, or whether the earliest launch date is already passed.

Investment modeling framework

Track three dates per relevant product/strength:

Earliest legally permitted generic launch date based on unexpired patents
Practical launch date based on settlement or design-around timing
Post-launch margin impact based on likely number of entrants and price erosion curves

What FDA regulatory status matters for finasteride and tadalafil in investment terms?

Bottom line: For investments, the decisive FDA issues are:

approval status of the specific marketed product (NDA vs ANDA presence),
whether any exclusivity still applies for a specific formulation strength,
and whether combination products have new regulatory hurdles.

Pathway implications

If the target is a reformulation: BE study burden and CMC validation become the critical gating items.
If the target is a new fixed-dose combination: clinical and regulatory evidence requirements increase timeline risk and capital needs.

How do finasteride and tadalafil compete commercially, and where is volume growth most likely?

Featured snippet answer: Commercial competition comes from:

generic pricing intensity for standalone finasteride and tadalafil products,
differentiation strategies for combination urology or sexual health regimens,
and brand pull via prescriber and patient adherence for longer-term ED or BPH management.

Where combination strategies can win

Simplified adherence for patients needing both BPH and ED management.
A single prescribing decision improves stickiness if pricing is favorable and tolerability is managed.
A differentiated product can keep pricing above pure generic equivalents if IP and payer positioning remain intact.

What formulations are protected for finasteride and tadalafil, and which delivery systems command IP value?

Bottom line: IP value usually concentrates in dosage form and release characteristics. For investment, the main risk is whether competing generics can satisfy performance targets without using the protected formulation.

Common protected formulation categories

controlled-release tablets
specific excipient blends improving dissolution
particle size or solid-state forms (more common for newer candidates than legacy APIs)
fixed-dose combination tablets with defined ratio and release behavior

What is the manufacturing and IP barrier for generic entry of finasteride and tadalafil?

Bottom line: For mature APIs, manufacturing barriers are generally moderate. IP barriers depend on whether the specific marketed product’s formulation and process are protected. If patents are weak or expired, the limiting factor becomes scale, supply reliability, and cost.

Investment lens

If the target owns manufacturing know-how that is protected by trade secrets and process patents, margin durability can improve.
If competitors can source APIs and replicate excipients readily, margin pressure accelerates post-launch.

How does a finasteride vs tadalafil standalone investment compare with a combination-product investment?

Bottom line: Standalone investments typically behave like commodity generics where returns track pricing and scale. Combination-product investments behave more like differentiated products where IP and regulatory specifics can support margin, but timelines and development costs are higher.

Comparison table: investment profile

Dimension	Finasteride standalone	Tadalafil standalone	Finasteride + Tadalafil combination
IP durability	Often low to moderate (secondary only)	Often low to moderate (secondary only)	Often higher if fixed-dose and dosing regimen claims survive
Generic erosion risk	High if patents unblocked	High if patents unblocked	Medium, depends on combination-specific claims
Development/regulatory burden	Low (generic or reformulation)	Low (generic or reformulation)	Higher (fixed-dose clinical/CMC and BE strategy)
Margin drivers	Cost and scale	Pricing power vs generics	Differentiation plus adherence and payer positioning
Primary investment risk	Patent unblocking, fast entry	Same as left	IP validity, settlement outcomes, and regulatory timeline

What revenue exposure should investors stress-test for finasteride and tadalafil?

Bottom line: Revenue exposure should be modeled by strength and geography, not by API alone. Even within the same drug, patent listings can differ by:

strength (e.g., 1 mg vs 5 mg for tadalafil),
dosage form,
or formulation.

Stress-test scenarios

Scenario 1: rapid generic entry at earliest unblocked dates across major strengths.
Scenario 2: delayed entry due to settlement or continuing litigation for a subset of strengths.
Scenario 3: partial design-around that removes infringement risk but still triggers price competition.
Scenario 4: payer substitution where formularies switch to lowest-cost alternatives despite residual brand presence.

Key Takeaways

Finasteride and tadalafil are mature APIs; investability depends on product-level secondary IP and the regulatory/Orange Book blocking status of specific marketed strengths and dosage forms.
For stand-alone products, investment returns largely track generic pricing and scale once core patents clear.
For combination products, the case is stronger only if fixed-dose and dosing regimen claims are enforceable and not easily design-around.
Revenue risk is best modeled by strength-by-strength earliest launch dates, litigation outcomes, and settlement-driven practical entry timing.
Manufacturing barriers are generally secondary; IP clarity and exclusivity timing are the primary drivers of downside.

FAQs

1) What typically remains patented for finasteride and tadalafil after composition-of-matter expiry?
Formulation, dosing regimens, and method-of-use claims for specific populations, plus fixed-dose combination claims when applicable.

2) How do Paragraph IV challenges translate into generic launch timing for these APIs?
If Orange Book-listed patents block approval, Paragraph IV disputes can delay or enable launch depending on infringement and validity findings, plus settlement terms.

3) Are fixed-dose combination patents usually easier to design around than standalone formulation patents?
They can be easier to design around when claims are narrow on ratios, excipients, or release profiles, but they can also be harder when multiple independent claims cover both composition and dosing.

4) What matters more for investment: FDA exclusivity or patent life for these legacy drugs?
Patent life and Orange Book listings typically dominate the barrier landscape for mature small molecules; FDA exclusivity matters mainly where still applicable to a specific formulation.

5) What is the biggest risk to margins post-generic entry for finasteride and tadalafil?
Speed of multi-entrant pricing erosion after the earliest legally permitted launch date, combined with payer substitution to lowest-cost alternatives.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
U.S. Food and Drug Administration. Drug Approval Process. https://www.fda.gov/drugs
FDA. Paragraph IV Certification and ANDA Litigation Framework (related guidance and background materials). https://www.fda.gov/

US Patents:	0
Applicants:	2
NDAs:	2

AI Deep Research

Questions you can ask:

Summary for FINASTERIDE AND TADALAFIL